The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation

Radiation Oncology

Volumn 5, Issue 1, 2010, Pages

  Rudner, Justine ^a   Ruiner, Carola Ellen ^a   Handrick, René ^b,c   Eibl, Hans Jörg ^d   Belka, Claus ^e   Jendrossek, Verena ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY OF APPLIED SCIENCES   (Germany)

^d MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

^e Clinic of Radiation Oncology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; ERUFOSINE; PROTEIN BCL 2; PROTEIN KINASE B INHIBITOR; UNCLASSIFIED DRUG; 2 MORPHOLINO 8 PHENYLCHROMONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ANTINEOPLASTIC AGENT; CHROMONE DERIVATIVE; ERUCYLPHOSPHO N,N,N TRIMETHYLPROPYLAMMONIUM; ERUCYLPHOSPHO-N,N,N-TRIMETHYLPROPYLAMMONIUM; MORPHOLINE DERIVATIVE; ORGANOPHOSPHATE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; QUATERNARY AMMONIUM DERIVATIVE; RADIOSENSITIZING AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL STRAIN LNCAP; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IONIZING RADIATION; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; RADIATION RESPONSE; WESTERN BLOTTING; CARCINOMA; CELL DEATH; DRUG ANTAGONISM; DRUG EFFECT; EVALUATION; PATHOLOGY; PROSTATE TUMOR; TIME; TREATMENT OUTCOME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA; CELL DEATH; CELL LINE, TUMOR; CHROMONES; HUMANS; MALE; MORPHOLINES; PHOSPHORIC ACID ESTERS; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUATERNARY AMMONIUM COMPOUNDS; RADIATION, IONIZING; RADIATION-SENSITIZING AGENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 78149493021     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-5-108     Document Type: Article

References (40)

1. Joniau S, Van Poppel H. Localized prostate cancer: can we better define who is at risk of unfavourable outcome?. BJU Int 2008, 101(Suppl 2):5-10. 10.1111/j.1464-410X.2007.07488.x, 18307686.
2. Welz S, Nyazi M, Belka C, Ganswindt U. Surgery vs. radiotherapy in localized prostate cancer. Which is best?. Radiat Oncol 2008, 3:23. 10.1186/1748-717X-3-23, 2553076, 18775078.
3. Harzstark AL, Ryan CJ. Novel therapeutic strategies in development for prostate cancer. Expert Opin Investig Drugs 2008, 17:13-22. 10.1517/13543784.17.1.13, 18095915.
4. Vogiatzi P, Cassone M, Claudio L, Claudio PP. Targeted therapy for advanced prostate cancer: Looking through new lenses. Drug News Perspect 2009, 22:593-601. 10.1358/dnp.2009.22.10.1443392, 20140279.
5. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2:489-501. 10.1038/nrc839, 12094235.
6. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510. 10.1038/onc.2008.245, 18794884.
7. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009, 9:550-562. 10.1038/nrc2664, 19629070.
8. Jendrossek V, Henkel M, Hennenlotter J, Vogel U, Ganswindt U, Muller I, Handrick R, Anastasiadis AG, Kuczyk M, Stenzl A, Belka C. Analysis of complex protein kinase B signalling pathways in human prostate cancer samples. BJU Int 2008, 102:371-382. 10.1111/j.1464-410X.2008.07703.x, 18476967.
9. Jendrossek V, Handrick R. Membrane targeted anticancer drugs: potent inducers of apoptosis and putative radiosensitisers. Curr Med Chem Anticancer Agents 2003, 3:343-353. 10.2174/1568011033482341, 12871080.
10. Rubel A, Handrick R, Lindner LH, Steiger M, Eibl H, Budach W, Belka C, Jendrossek V. The membrane targeted apoptosis modulators erucylphosphocholine and erucylphosphohomocholine increase the radiation response of human glioblastoma cell lines in vitro. Radiat Oncol 2006, 1:6. 10.1186/1748-717X-1-6, 1475859, 16722524.
11. Vink SR, Schellens JH, Beijnen JH, Sindermann H, Engel J, Dubbelman R, Moppi G, Hillebrand MJ, Bartelink H, Verheij M. Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours. Radiother Oncol 2006, 80:207-213. 10.1016/j.radonc.2006.07.032, 16914220.
12. Vink SR, van Blitterswijk WJ, Schellens JH, Verheij M. Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy. Cancer Treat Rev 2007, 33:191-202. 10.1016/j.ctrv.2006.12.001, 17287087.
13. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26:1324-1337. 10.1038/sj.onc.1210220, 2930981, 17322918.
14. Handrick R, Rubel A, Faltin H, Eibl H, Belka C, Jendrossek V. Increased cytotoxicity of ionizing radiation in combination with membrane-targeted apoptosis modulators involves downregulation of protein kinase B/Akt-mediated survival-signaling. Radiother Oncol 2006, 80:199-206. 10.1016/j.radonc.2006.07.021, 16916558.
15. Gajate C, Mollinedo F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 2007, 109:711-719. 10.1182/blood-2006-04-016824, 17003375.
16. Jendrossek V, Muller I, Eibl H, Belka C. Intracellular mediators of erucylphosphocholine-induced apoptosis. Oncogene 2003, 22:2621-2631. 10.1038/sj.onc.1206355, 12730676.
17. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003, 2:1093-1103.
18. Momota H, Nerio E, Holland EC. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res 2005, 65:7429-7435. 10.1158/0008-5472.CAN-05-1042, 16103096.
19. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008, 11:32-50. 10.1016/j.drup.2007.11.003, 2442829, 18166498.
20. Pesche S, Latil A, Muzeau F, Cussenot O, Fournier G, Longy M, Eng C, Lidereau R. PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene 1998, 16:2879-2883. 10.1038/sj.onc.1202081, 9671408.
21. Henke G, Lindner LH, Vogeser M, Eibl HJ, Worner J, Muller AC, Bamberg M, Wachholz K, Belka C, Jendrossek V. Pharmacokinetics and biodistribution of Erufosine in nude mice--implications for combination with radiotherapy. Radiat Oncol 2009, 4:46. 10.1186/1748-717X-4-46, 2773776, 19852786.
22. Berger MR, Tsoneva I, Konstantinov SM, Eibl H. Induction of apoptosis by erucylphospho-N, N, N-trimethylammonium is associated with changes in signal molecule expressionand location. Ann N Y Acad Sci 2003, 1010:307-310. 10.1196/annals.1299.054, 15033740.
23. Fiegl M, Lindner LH, Juergens M, Eibl H, Hiddemann W, Braess J. Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs. Cancer Chemother Pharmacol 2008, 62:321-329. 10.1007/s00280-007-0612-7, 2755757, 17922125.
24. Konigs SK, Pallasch CP, Lindner LH, Schwamb J, Schulz A, Brinker R, Claasen J, Veldurthy A, Eibl H, Hallek M, Wendtner CM. Erufosine, a novel alkylphosphocholine, induces apoptosis in CLL through a caspase-dependent pathway. Leuk Res 2010, 34:1064-9. 10.1016/j.leukres.2009.12.003, 20092894.
25. Zaharieva MM, Konstantinov SM, Pilicheva B, Karaivanova M, Berger MR. Erufosine: a membrane targeting antineoplastic agent with signal transduction modulating effects. Ann N Y Acad Sci 2007, 1095:182-192. 10.1196/annals.1397.022, 17404031.
26. Fu L, Kim YA, Wang X, Wu X, Yue P, Lonial S, Khuri FR, Sun SY. Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res 2009, 69:8967-8976. 10.1158/0008-5472.CAN-09-2190, 19920197.
27. Veenman L, Alten J, Linnemannstons K, Shandalov Y, Zeno S, Lakomek M, Gavish M, Kugler W. Potential involvement of F(0)F (1)-ATP(synth)ase and reactive oxygen species in apoptosis induction by the antineoplastic agent erucylphosphohomocholine in glioblastoma cell lines: A mechanism for induction of apoptosis via the 18 kDa mitochondrial translocator protein. Apoptosis 2010, 15:753-68. 10.1007/s10495-010-0460-5, 20107899.
28. Yosifov DY, Konstantinov SM, Berger MR. Erucylphospho-N, N, N-trimethylpropylammonium shows substantial cytotoxicity in multiple myeloma cells. Ann N Y Acad Sci 2009, 1171:350-358. 10.1111/j.1749-6632.2009.04694.x, 19723075.
29. Martelli AM, Papa V, Tazzari PL, Ricci F, Evangelisti C, Chiarini F, Grimaldi C, Cappellini A, Martinelli G, Ottaviani E, et al. Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. Leukemia 24:687-698. 10.1038/leu.2010.32, 20200557.
30. Chee KG, Longmate J, Quinn DI, Chatta G, Pinski J, Twardowski P, Pan CX, Cambio A, Evans CP, Gandara DR, Lara PN. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer 2007, 5:433-437. 10.3816/CGC.2007.n.031, 18272025.
31. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 1997, 7:261-269. 10.1016/S0960-9822(06)00122-9, 9094314.
32. Anderson KE, Coadwell J, Stephens LR, Hawkins PT. Translocation of PDK-1 to the plasma membrane is important in allowing PDK-1 to activate protein kinase B. Curr Biol 1998, 8:684-691. 10.1016/S0960-9822(98)70274-X, 9637919.
33. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101. 10.1126/science.1106148, 15718470.
34. Bozulic L, Surucu B, Hynx D, Hemmings BA. PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell 2008, 30:203-213. 10.1016/j.molcel.2008.02.024, 18439899.
35. Lee JT, Lehmann BD, Terrian DM, Chappell WH, Stivala F, Libra M, Martelli AM, Steelman LS, McCubrey JA. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 2008, 7:1745-1762. 2593475, 18594202.
36. Song R, Harris LD, Pettaway CA. Downmodulation of Bcl-2 sensitizes metastatic LNCaP-LN3 cells to undergo apoptosis via the intrinsic pathway. Prostate 70:571-583.
37. Ghobrial IM, Roccaro A, Hong F, Weller E, Rubin N, Leduc R, Rourke M, Chuma S, Sacco A, Jia X, et al. Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia. Clin Cancer Res 16:1033-1041. 10.1158/1078-0432.CCR-09-1837, 20103671.
38. Berkovic D, Bensch M, Bertram J, Wille T, Haase D, Binder C, Fleer EA. Effects of hexadecylphosphocholine on thrombocytopoiesis. Eur J Cancer 2001, 37:503-511. 10.1016/S0959-8049(00)00394-4, 11267861.
39. Ergezinger K, Vehmeyer K, Unger C. Stimulation of human hematopoietic progenitor cells by the alkylphosphocholines hexadecylphosphocholine and hexadecyl-N, N, N-trimethyl-hexanolamine. Anticancer Res 1999, 19:3213-3219.
40. Lindner LH, Eibl H, Hossann M, Vogeser M. Quantification of erufosine, the first intravenously applicable alkylphosphocholine, in human plasma by isotope dilution liquid chromatography-tandem mass spectrometry using a deuterated internal standard. J Chromatogr B Analyt Technol Biomed Life Sci 2008, 869:16-19. 10.1016/j.jchromb.2008.05.007, 18508417.